These data support the actual treatment guidelines supporting the new combinations of endocrine therapies plus targeted therapies as first-line or second-line treatments in breast cancer patients with HR-positive, HER2-negative metastatic disease [367]. This evidence concerns the gene ERBB2 and metastatic neoplasm.